GlassScriptPhysician profile
Supriya Rastogi
NPI 1235522905
$6,966.84
in general payments reported to CMS, 2019-2025
23 companies · $5,232 in 2025
The $5,232 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.07 · 2022: $96.55 · 2023: $363 · 2024: $1,264 · 2025: $5,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,291 · Consulting Fee: $1,488 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,290.72 |
| Consulting Fee | $1,487.50 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $2,477.62 | 2025 | Adbry, Anzupgo |
| Abbvie INC. | $862.69 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $483.78 | 2024-2025 | |
| Incyte Corporation | $469.29 | 2022-2025 | Opzelura |
| Amgen INC. | $459.63 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $437.70 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $354.77 | 2024-2025 | |
| Janssen Biotech, INC. | $349.74 | 2024-2025 | Tremfya |
| Galderma Laboratories, L.P. | $224.07 | 2025 | Nemluvio, Aklief |
| Botanix Sb INC | $159.87 | 2025 | Sofdra |
| Ucb, INC. | $141.85 | 2024-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $99.61 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $71.82 | 2024-2025 | |
| Fidia Pharma USA INC. | $64.95 | 2024-2025 | |
| Pfizer INC. | $64.90 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $54.41 | 2024-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $50.55 | 2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $41.99 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $24.82 | 2025 | Valchlor |
| Mayne Pharma Commercial LLC | $24.39 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.10 | 2025 | Cabtreo |
| Strata Skin Sciences, INC. | $17.22 | 2025 | Xtrac |
| Novo Nordisk INC | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supriya Rastogi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.